Collaborative Arrangements - Molecular Associates Inc (Details) - USD ($)	1 Months Ended		12 Months Ended
	Apr. 30, 2021	Jun. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Investment in non-marketable securities			$ 7,630,000	$ 2,000,000	$ 0
Contract liabilities, deferred revenue			$ 6,335,000	4,791,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected timing of satisfaction, period			1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected timing of satisfaction, period			1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected timing of satisfaction, period			1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected timing of satisfaction, period
Molecular Assemblies, Inc. | Master Collaboration & Research Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized from transactions			$ 2,000,000	$ 900,000
Molecular Assemblies, Inc. | Master Collaboration & Research Agreement | Maximum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected timing of satisfaction, period		14 months
Molecular Assemblies, Inc. | Master Collaboration & Research Agreement | Bonus Goal Met
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of days for payment		30 days
Molecular Assemblies, Inc. | Commercialization And Enzyme Supply Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate commercial sales, milestone		$ 5,000,000
Molecular Assemblies, Inc. | Commercialization And Enzyme Supply Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-12-01
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected timing of satisfaction, period						6 months
Molecular Assemblies, Inc. | Commercialization And Enzyme Supply Agreement | Revenue sharing arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities, deferred revenue						$ 500,000
Series A and B Preferred Stock | Molecular Assemblies, Inc. | Master Collaboration & Research Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Investment owned, balance (in shares)			3,491,505	714,171
Molecular Assemblies, Inc. | Series A Preferred Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Investment owned, balance (in shares)	1,000,000	1,587,050
Investment in non-marketable securities	$ 600,000	$ 1,000,000
Molecular Assemblies, Inc. | Series A and B Preferred Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Investment in non-marketable securities			$ 12,700,000	$ 1,500,000